[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371030-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371030-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comparative-transcriptome-atlas-as-an-assistive-modality-for-complex-classification-of-rare-kidney-cancers-received-30-january-2025","Comparative transcriptome atlas as an assistive modality for complex classiﬁcation of rare kidney cancers - Received 30 January 2025","","Molecularly characterizing modalities are needed to support the complex classification of rare kidney cancers, including unclassiﬁed renal cell carcinoma arising from complex histology. The study demonstrates utility of a comparative transcriptome atlas for assisting classification by leveraging RNA-seq from 219 renal tumors, where clustering aligns with WHO 2022 histological classification. The atlas may help define the molecular traits of unclassiﬁed RCC and supports prediction of patient outcomes, addressing gaps that can otherwise cause over- or under-treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comparative-transcriptome-atlas-as-an-assistive-modality-for-complex-classification-of-rare-kidney-cancers-received-30-january-2025/371030/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comparative-transcriptome-atlas-as-an-assistive-modality-for-complex-classification-of-rare-kidney-cancers-received-30-january-2025/371030.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is there an unmet medical need for rare kidney cancer classification?","Question",{"text":63,"@type":64},"Rare kidney cancers often show complex histology, and some cases are diagnosed as unclassiﬁed RCC. Limited molecularly characterizing modalities can lead to over- or under-treatment or non-evidence-based drug selection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the comparative transcriptome atlas assist in classification?",{"text":68,"@type":64},"It uses RNA-seq data for unsupervised clustering, and the resulting groups are largely consistent with histological classification based on WHO 2022. It is positioned as an assistive modality for complex classification.",{"name":70,"@type":61,"acceptedAnswer":71},"What potential value does the atlas offer for unclassiﬁed RCC?",{"text":72,"@type":64},"The atlas may help define molecular characteristics of unclassiﬁed RCC and might predict patient outcome, improving the ability of clinicians to support personalized medicine.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371030,1790257176,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article [https://doi.org/10.1038/s41467-025-65303-z](https://doi.org/10.1038/s41467-025-65303-z)  \nComparative transcriptome atlas as an assistive modality for complex classiﬁcation of rare kidney cancers  \nReceived: 30 January 2025  \n\n| Accepted: 7 October 2025 |\n| --- |\n| |\n| Check for updates |\n\nRyosuke Jikuya 1,2, Todd A. Johnson 2, Erika Muraoka3, Go Noguchi 1, Shigekatsu Maekawa 4, Wataru Obara4, Kazuyuki Numakura5,  \nTomonori Habuchi5, Kazuhiro Maejima2, Shota Sasagawa2, Yuki Kanazashi2, Hwajin Lee6,7,8, Woo Jeung Song6, Hajime Sasagawa9, Taku Mitome1,  \nShinji Ohtake1, Sachi Kawaura1, Yasuhiro Iribe1, Kota Aomori1, Hirotaka Nagasaka1, Tomoyuki Tatenuma1, Daiki Ueno1, Mitsuru Komeya1, Hiroki Ito1, Yusuke Ito1, Kentaro Muraoka1, Takashi Kawahara1, Mitsuko Furuya10, Ikuma Kato3,  \nHaruka Hamanoue 11, Akira Nishiyama 12,13, Tomohiko Tamura 12,13, Masaya Baba 14, Toshio Suda 14, Tatsuhiko Kodama15, Takehiko Ogawa 16, Hiroji Uemura1, Masahiro Yao1, Toyonori Tsuzuki 17, Yoji Nagashima18, Yuji Miura19, Go Kimura 20, Seiya Imoto21, Yukihide Momozawa 9, Satoshi Fujii3, Kazuhide Makiyama1, Takanori Hasegawa22, Brian M. Shuch23,  \nChristopher J. Ricketts 24, Laura S. Schmidt 24,25, W. Marston Linehan 24, Hidewaki Nakagawa 2  & Hisashi Hasumi 1   \nThere is a great unmet medical need for development of molecularly characterizing modalities to assist in the complex classiﬁcation of rare kidney cancers, some of which are diagnosed as unclassiﬁed renal cell carcinoma (unclassiﬁed RCC) due to complex histology. Here we show utility of the comparative transcriptome atlas as an assistive modality for complex classiﬁcation of rare kidney cancers. Where  \n52 rare kidney cancers identiﬁes very few clinically signiﬁcant variants in a subset ofcases, unsupervised clustering results of RNA-seq data from 219renal tumors including 140 rare kidney cancers are largely consistent with the histological classiﬁcation based on WHO2022 classiﬁcation. Additionally, the comparative transcriptome atlas may provide an opportunity to deﬁne the molecular characteristics of unclassiﬁed RCC and might predict patient outcome. These ﬁndings support the comparative transcriptome atlas as an assistive modality for complex classiﬁcation of rare kidney cancers.  \nThe lack of an assistive modality for complex classiﬁcation of rare kidney cancers sometimes leads to over- or under-treatment, or random drug selection without any clear evidence in the management of these rare kidney cancers. Most studies, including The Cancer Genome Atlas Program (TCGA) and TRACERx Renal study, have been focused on renal tumorigenesis of clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell  \ncarcinoma(ChRCC)1–4. Most clinical trials have been designed for these major histological types, and very few clinical studies have been conducted on rare subtypes, resulting in a great unmet medical need for the development of precision medicine for patients with rare subtypes5,6. Additionally, the genetic panel testing incorporated into routine clinical practice is unable to identify gene variants in a considerable number of these rare kidney cancers.  \nas whole genome sequencing (WGS) of  \nA full list of afﬁliations appears at the end of the paper. e-mail: [hidewaki@riken.jp](hidewaki@riken.jp); [hasumi@yokohama-cu.ac.jp](hasumi@yokohama-cu.ac.jp)  \nHistology of rare kidney cancers is complex; complicated immunohistochemistry (IHC) or ﬂuorescence in situ hybridization is necessary for pathological diagnosis7,8. The number of histological subtypes of renal tumors is increasing in the WHO classiﬁcation of urinary and male genital tumors; 12 subtypes in WHO2004, 16 subtypes in WHO2016, and 21 subtypes in WHO2022 (5th edition)9–11. The WHO2022 classiﬁcation has classiﬁed renal tumors into various subtypes, including mucinous tubular and spindle cell carcinoma (MTSCC), clear cell papillary RCC (ccpRCC), tubulocystic RCC (tcRCC), multilocular cystic r","cbCainEBu9yaYqtK","https://ap.wps.com/l/cbCainEBu9yaYqtK","pdf",3436646,15,"English","# Background and unmet need\n# Study approach and comparative transcriptome atlas\n# Clinical implications for classification and outcomes\n# Limitations of existing molecular testing\n# Histology complexity in WHO classifications\n# Molecular drivers and pathway insights","[{\"question\":\"Why is there an unmet medical need for rare kidney cancer classification?\",\"answer\":\"Rare kidney cancers often show complex histology, and some cases are diagnosed as unclassiﬁed RCC. Limited molecularly characterizing modalities can lead to over- or under-treatment or non-evidence-based drug selection.\"},{\"question\":\"How does the comparative transcriptome atlas assist in classification?\",\"answer\":\"It uses RNA-seq data for unsupervised clustering, and the resulting groups are largely consistent with histological classification based on WHO 2022. It is positioned as an assistive modality for complex classification.\"},{\"question\":\"What potential value does the atlas offer for unclassiﬁed RCC?\",\"answer\":\"The atlas may help define molecular characteristics of unclassiﬁed RCC and might predict patient outcome, improving the ability of clinicians to support personalized medicine.\"}]","Comparative transcriptome atlas as an assistive modality for complex classiﬁcation of rare kidney cancers - Received 30 January 2025 | PDF",1790191075,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8921c739e88cc22d6ead79237bf6c450.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80a5a5266eb23be064ea99aa5eab7f21.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65cc07de35a3389c0b7d58d8e307aeaa.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/179173329188fafdc057b0426d648f6a.webp",980,1301]